Menu Close
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
    • The Flipside
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • #JHM Chat
  • Industry Content
    • Patient Monitoring with Tech
An Official Publication of
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
    • The Flipside
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • #JHM Chat
  • Industry Content
    • Patient Monitoring with Tech

In the Literature

  • Article

    Semaglutide in Patients with HFpEF and Obesity

    May 1, 2024

    Dr. Cepeda Mora Clinical question: Is semaglutide an effective heart failure treatment in patients with heart failure with preserved ejection fraction (HFpEF) and obesity? Background: HFpEF is...

  • Article

    Frailty Assessment and Perioperative Adverse Cardiovascular Events After Noncardiac Surgery

    May 1, 2024

    Dr. Chandler Clinical question: Can a frailty assessment tool be used to identify patients at higher risk for major adverse cardiac events (MACE) prior to noncardiac surgery? Background: Studies...

  • Article

    Black Patients More Likely to Experience Security Emergency Responses

    May 1, 2024

    Colby Feeney, MD, FHM Clinical question: Do race and ethnicity predict the use of security emergency responses (SER) in a non-psychiatric inpatient setting? Background: Studies have demonstrated...

  • Article

    Piperacillin-tazobactam Doesn’t Increase Risk of AKI Compared to Cefepime

    May 1, 2024

    Dr. Rhodes Clinical question: Do piperacillin-tazobactam and cefepime have similar risks of acute kidney injury (AKI)? Background: Observational studies have shown an association between...

  • Article

    Back Off the Baclofen: Increased Risk of Encephalopathy

    May 1, 2024

    Dr. Sata Clinical question: Compared to other muscle relaxants, does baclofen increase the risk of encephalopathy? Background: Baclofen is a GABAergic muscle relaxant that is useful for patients...

  • Article

    Torsemide or Furosemide After Discharge in Patients Hospitalized with HF

    April 1, 2024

    Clinical question: Is there a mortality difference in patients discharged on torsemide versus furosemide after heart failure hospitalization? Background: Torsemide has been thought to be superior to...

  • Article

    Semaglutide in Patients with HFpEF and Obesity

    April 1, 2024

    Clinical question: Does treatment with semaglutide lead to a reduction in symptoms and physical limitations and improve exercise function in patients with heart failure with preserved ejection...

  • Article

    VTEs and Their Effects on Patients with AE-COPD

    April 1, 2024

    Clinical question: How common are venous thromboembolisms (VTEs) in patients presenting with acute exacerbation of chronic obstructive pulmonary disease (AE-COPD) and what is the effect on prognosis,...

  • Article

    Risk and Benefit of Secondary Prevention with Aspirin Versus P2Y12 Inhibitor in CAD Patients

    April 1, 2024

    Clinical question: In patients with coronary artery disease (CAD), what is the difference in risk and benefit between secondary prevention with aspirin (ASA) versus a P2Y12 inhibitor? Background:...

  • Article

    Cefepime Versus Piperacillin-tazobactam in Adults Hospitalized with Acute Infection

    April 1, 2024

    Clinical question: Are there increased adverse outcomes with the utilization of cefepime or piperacillin-tazobactam? Background: Hospitalists frequently prescribe cefepime or piperacillin-tazobactam...

Previous1 … 7 8 9 10 11 … 25Next
  • About The Hospitalist
  • Contact Us
  • The Editors
  • Editorial Board
  • Authors
  • Publishing Opportunities
  • Subscribe
  • Advertise
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies.
    ISSN 1553-085X
  • Privacy Policy
  • Terms and Conditions
  • SHM’s DE&I Statement
  • Cookie Preferences